Christy Oliger
Director/Board Member bij KARYOPHARM THERAPEUTICS INC.
Vermogen: - $ op 31-03-2024
Profiel
Christy J.
Oliger is currently serving as an Independent Director at Karyopharm Therapeutics, Inc. since 2020, as well as an Independent Director at Replimune Group, Inc. since 2021, and a Non-Executive Director at LAVA Therapeutics NV since 2023.
Previously, she held positions as an Independent Director at Sierra Oncology, Inc. from 2021 to 2022, as an Independent Director at Reata Pharmaceuticals, Inc. from 2021 to 2023, as a Director at Rayzebio, Inc. from 2023 to 2024, and as the Senior Vice President & Head-Oncology Business at Genentech, Inc. from 2017 to 2020.
Ms. Oliger completed her undergraduate degree at the University of California, Santa Barbara.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
REPLIMUNE GROUP, INC.
-.--% | 01-04-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
| 24-05-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Christy Oliger
| Bedrijven | Functie | Begin |
|---|---|---|
| KARYOPHARM THERAPEUTICS INC. | Director/Board Member | 28-08-2020 |
| REPLIMUNE GROUP, INC. | Director/Board Member | 01-12-2021 |
| LAVA THERAPEUTICS N.V. | Director/Board Member | 09-03-2023 |
Eerdere bekende functies van Christy Oliger
| Bedrijven | Functie | Einde |
|---|---|---|
| RAYZEBIO, INC. | Director/Board Member | 26-02-2024 |
| REATA PHARMACEUTICALS, INC. | Director/Board Member | 26-09-2023 |
| SIERRA ONCOLOGY, INC. | Director/Board Member | 01-07-2022 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01-07-2020 |
Opleiding van Christy Oliger
| University of California, Santa Barbara | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| KARYOPHARM THERAPEUTICS INC. | Health Technology |
| REPLIMUNE GROUP, INC. | Health Technology |
| LAVA THERAPEUTICS N.V. | Health Technology |
| RAYZEBIO, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
